M&A Deal Summary

Pacific Biosciences of California Acquires Circulomics

On August 3, 2021, Pacific Biosciences of California acquired life science company Circulomics

Acquisition Highlights
  • This is Pacific Biosciences of California’s 2nd transaction in the Life Science sector.
  • This is Pacific Biosciences of California’s 2nd transaction in the United States.
  • This is Pacific Biosciences of California’s 1st transaction in Maryland.

M&A Deal Summary
Date 2021-08-03
Target Circulomics
Sector Life Science
Buyer(s) Pacific Biosciences of California
Deal Type Add-on Acquisition

Target

Circulomics

Baltimore, Maryland, United States
Circulomics is a biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows. Circulomics use micro-, nano-, and single-molecule technologies to streamline every step in the genomics workflow from sample preparation to assays and detection instruments. Circulomics was founded in 2009 and is based in Baltimore, Maryland.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pacific Biosciences of California

Menlo Park, California, United States
Category Company
Founded 2004
Sector Life Science
DESCRIPTION

Pacific Biosciences of California, Inc. offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 2 of 3
State (Maryland) 1 of 1
Country (United States) 2 of 3
Year (2021) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-20 Omniome

San Diego, California, United States

Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering high sequencing accuracy. The company's vision is to be the most trusted DNA sequencing platform and broadly support clinical sequencing. Omniome was formed in 2013 and is based in San Diego, California.

Buy $600M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-08-02 Apton

Pleasanton, California, United States

Apton is a developer of Super-Res™ sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing. Apton has re-imagined the optical systems for sequencing using super-resolution to evaluate molecules spaced closer than a wavelength of light. Apton's Super-Res™ technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs. Apton was founded in 2012 and is based in Pleasanton, California.

Buy $110M
Mergr

Product

Company

Legal